Emmaus Life Sciences Stock Price - EMMA

2.77
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
2.77
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Emmaus Life Sciences Inc EMMA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 2.77 0.00 0.00 0.00 2.77 20:00:00
Bid Price Ask Price Spread Spread % News
2.75 2.87 0.12 4.18% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.77 USD

Emmaus Life Sciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 134.27M 48.47M 10.99M $ 1.32M $ - -11.34 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
41.22k $ - 0.00% 49.00 77.30%

more financials information »

Emmaus Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EMMA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year9.209.202.493.69156,033-6.43-69.89%
3 Years9.209.202.493.69156,033-6.43-69.89%
5 Years9.209.202.493.69156,033-6.43-69.89%

Emmaus Life Sciences Description

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis, and Cell Sheet Engineering.


Your Recent History
NASDAQ
EMMA
Emmaus Lif..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.